Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Teladoc Health (NYSE:TDOC) Stock Price

Teladoc Health (NYSE:TDOC) had its price objective boosted by Deutsche Bank Aktiengesellschaft from $10.00 to $12.00 in a research note published on Friday morning, Benzinga reports. They currently have a hold rating on the health services provider’s stock.

Several other equities analysts have also commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $10.00 price target on shares of Teladoc Health in a research report on Tuesday, August 20th. DA Davidson dropped their price target on shares of Teladoc Health from $12.00 to $8.00 and set a “neutral” rating for the company in a research report on Thursday, August 1st. Evercore ISI boosted their price objective on shares of Teladoc Health from $8.00 to $9.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 8th. Oppenheimer decreased their price objective on shares of Teladoc Health from $21.00 to $17.00 and set an “outperform” rating for the company in a research note on Thursday, August 1st. Finally, Barclays boosted their price objective on shares of Teladoc Health from $10.00 to $12.00 and gave the stock an “overweight” rating in a research note on Thursday. Fourteen analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $11.97.

Teladoc Health Trading Up 2.3 %

Shares of NYSE:TDOC traded up $0.21 during trading on Friday, reaching $9.21. The stock had a trading volume of 6,593,949 shares, compared to its average volume of 4,955,174. The business has a fifty day moving average price of $8.48 and a 200-day moving average price of $9.69. The company has a quick ratio of 1.62, a current ratio of 1.66 and a debt-to-equity ratio of 0.66. The stock has a market cap of $1.58 billion, a P/E ratio of -1.60 and a beta of 0.90. Teladoc Health has a fifty-two week low of $6.76 and a fifty-two week high of $22.54.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, October 30th. The health services provider reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.10. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 9.40%. The business had revenue of $640.51 million during the quarter, compared to analyst estimates of $630.50 million. As a group, analysts anticipate that Teladoc Health will post -1.18 earnings per share for the current fiscal year.

Insider Buying and Selling at Teladoc Health

In related news, Director Thomas Mckinley acquired 7,000 shares of Teladoc Health stock in a transaction on Tuesday, August 6th. The shares were purchased at an average cost of $7.57 per share, for a total transaction of $52,990.00. Following the purchase, the director now directly owns 31,077 shares of the company’s stock, valued at $235,252.89. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Teladoc Health news, CMO Stephany Verstraete sold 15,000 shares of the stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $7.60, for a total transaction of $114,000.00. Following the transaction, the chief marketing officer now directly owns 45,158 shares in the company, valued at $343,200.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Thomas Mckinley bought 7,000 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were acquired at an average cost of $7.57 per share, for a total transaction of $52,990.00. Following the completion of the acquisition, the director now directly owns 31,077 shares of the company’s stock, valued at $235,252.89. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold 36,588 shares of company stock worth $268,831 in the last ninety days. 0.95% of the stock is owned by insiders.

Institutional Trading of Teladoc Health

A number of institutional investors and hedge funds have recently modified their holdings of the business. Point72 Asset Management L.P. raised its holdings in shares of Teladoc Health by 221.9% during the second quarter. Point72 Asset Management L.P. now owns 5,303,123 shares of the health services provider’s stock worth $51,865,000 after purchasing an additional 3,655,436 shares during the period. Rubric Capital Management LP acquired a new stake in shares of Teladoc Health during the second quarter worth $45,267,000. Clearline Capital LP raised its holdings in shares of Teladoc Health by 395.6% during the second quarter. Clearline Capital LP now owns 4,364,201 shares of the health services provider’s stock worth $42,682,000 after purchasing an additional 3,483,665 shares during the period. Assenagon Asset Management S.A. acquired a new stake in shares of Teladoc Health during the third quarter worth $15,801,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Teladoc Health by 1.7% during the second quarter. Bank of New York Mellon Corp now owns 916,129 shares of the health services provider’s stock worth $8,960,000 after purchasing an additional 14,910 shares during the period. 76.82% of the stock is owned by institutional investors and hedge funds.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.